INTRODUCTION {#S5}
============

Deficient mismatch repair activity (dMMR) is found in 15% of colorectal cancers (CRC). MMR genes remove errors in the form of deletions or insertions of DNA nucleotides that occur during the mitotic process. In the presence of defective MMR activity, mismatched nucleotides are incorporated into cells thus predisposing them to malignant transformation with a hypermutated phenotype.^[@R1]^ Microsatellite instability (MSI) is the hallmark of mismatch repair deficiency. In 3% of CRC cases dMMR is caused by Lynch syndrome (LS)^[@R2]^ through germline mutations in the *MLH1*, *MSH2*, *MSH6*, *PMS2* or *EPCAM*^[@R3]^ genes and in 12% of cases it is caused by sporadic inactivation of *MLH1* (hypermethylation of the *MLH1* gene promoter, *MLH1*-hm). In rare cases, it is caused by bi-allelic germline MMR mutations (Constitutional dMMR Deficiency syndrome)^[@R4]^ and more recently, the bi-allelic occurrence of two somatic MMR mutations were shown to explain some dMMR cases.^[@R5],[@R6]^

Tumors with dMMR have been associated with specific characteristics such as right-sided location, poor differentiation, lymphocytic infiltration, and mucinous features.^[@R7]^ They are also less likely to metastasize and tend to have a better overall survival in the early stages.^[@R8]--[@R10]^ Differences in clinical features and outcomes between LS-associated and *MLH1*-hm tumors have not been well explored, and many studies categorize the two subtypes without regard to their divergent origins as MSI-high tumors. Poynter et al. examined the incidence of *MLH1*-hm in MSI-high CRC in a population-based cohort and found MSI-high hypermethylated tumors to be significantly associated with older age, female gender, and a right-sided location when compared to MSI-high non-methylated tumors.^[@R11]^ Tumor genomic studies suggest that there is a molecular difference between tumors that develop in the setting of an inherited MMR mutation when compared with sporadic *MLH1*-hm tumors, most notably with regard to the association of a *BRAF* mutation. *BRAF* mutations are observed in up to 60--70% of *MLH1-*hm tumors but very rarely occur in LS-associated tumors.^[@R12],[@R13]^

Universal immunohistochemistry (IHC) screening for MMR proteins in all CRC tumors was recommended by the Evaluation of Genomic Applications in Practice and Prevention workgroup of the CDC in 2009^[@R12]^, by the National Comprehensive Cancer Network in March 2014^[@R14]^ and by the US Multi-Society Task Force in August 2014.^[@R15]^ Data for MMR IHC in CRC patients is available at The Ohio State University since 1998 and has been performed routinely on all CRC tumors since 2006. The objective of this study was to retrospectively explore differences in clinical presentation and outcomes in patients with dMMR CRC related to LS vs. sporadic *MLH1*-hm.

MATERIALS AND METHODS {#S6}
=====================

Patients {#S7}
--------

Consecutive patients with CRC who had dMMR on IHC performed from May 1998 to May 2012 were included in the study. This consisted of patients enrolled in the Columbus LS study^[@R2]^, and also included all CRC patients diagnosed after 2006. Patients with *MLH1*-hm tumors were identified by either absent MLH1 protein on IHC and *BRAF* mutation or hypermethylation of the *MLH1* promoter region. Patients classified as having LS had confirmed germline MMR mutations. Patients with dMMR tumors who did not have conclusive testing (i.e. not diagnosed as either LS or *MLH1*-hm tumor) were excluded from further analysis.

Recurrent disease was defined as a recurrent tumor at the anastomotic site or distant metastasis that developed within 5 years of a primary diagnosis at stage I--III. Patients with less than 2 years of follow-up were excluded from this analysis. Synchronous tumors were defined as two colorectal tumors that were discovered simultaneously or within 6 months of each other. Metachronous colorectal tumors were discovered more than 6 months from each other.^[@R16]^

Baseline information on demographics, tumor characteristics, treatment and survival were obtained from medical charts. All tumors were pathologically reported according to the American Joint Committee on Cancer, 7^th^ edition for CRC.^[@R17]^ For patients with synchronous tumors, the tumor with higher stage was documented as the primary. The institutional review board at the Ohio State University approved this study.

MSI, Immunohistochemistry and *MLH1* hypermethylation testing {#S8}
-------------------------------------------------------------

For patients on the Columbus LS study, DNA was extracted from paraffin-embedded tumor, normal adjacent tissue and blood. IHC for the four MMR proteins, MSI testing, *MLH1*-hm testing, and germline genetic testing (sequencing and multiplex ligation probe assay) for the four MMR genes was performed as previously described.^[@R2],[@R18]--[@R20]^ Tumor tissue was stained for MLH1 (Novacastra, Buffalo Grove, IL; NCL-L-MLH-1), MSH2 (Calbiochem, \[Merck Biosciences AG\], Basel-Land, Switzerland; NA27), MSH6 (Epitomics Inc, Burlingame, CA; AC-0047) and PMS2 (BD Pharmingen, San Jose, CA; 556415) proteins with IHC. For patients enrolled onto the Columbus LS study, the promoter region of *MLH1* was assessed for methylation with methylation-specific polymerase chain reaction.^[@R21]^ In clinical cases since 2005, DNA was modified with sodium bisulfite and the bisulfite treated DNA was sequenced by PyroMark MD (Quiagen) for *MLH1* methylation analysis. Sequencing of exon 15 of the *BRAF* gene was performed in some clinical cases to identify any activating mutations. Approximately 25 to 50 ng of tumor DNA was amplified in a 15-μL polymerase chain reaction (PCR) using Promega's GoTaq master mix (Promega, Madison, WI). PCR products were analyzed using an ABI3700 sequencer (Life Technologies, Grand Island, NY) following suitable amplification.

Survival analysis {#S9}
-----------------

Age at diagnosis was defined as the age when a CRC diagnosis was confirmed. Overall survival (OS) was defined as time from diagnosis to death from any cause. Patients who developed a metachronous primary CRC were censored at the time of diagnosis of the second tumor. Patients who were alive were censored at their last follow-up appointment date. Cancer-specific survival (CSS) was defined as time from diagnosis to a CRC related death and we chose to censor patients who developed a second cancer (except for non-melanoma skin cancer), died from other causes or were lost to follow-up.

Statistical Analysis {#S10}
--------------------

Descriptive statistics (median with quartiles for age, follow-up time and CEA and mean with standard deviation for other continuous variables and frequency for categorical variables) were provided to summarize the patient population. Student's t-test and Chi-square were used to compare the difference of continuous and categorical parameters in LS vs. *MLH1*-hm groups respectively. Kaplan Meier estimation and log-rank test were used to compare the difference of OS and CSS between the two groups. Stage of cancer and age at diagnosis were considered as a covariate in the Cox proportional hazards model in the survival analysis. All statistical analyses were performed using SAS software, version 9.4 (SAS Institute Inc., Cary, NC).

RESULTS {#S11}
=======

Patient characteristics, stage at diagnosis and location of tumor {#S12}
-----------------------------------------------------------------

A total of 189 patients with CRC and documented MMR deficiency by IHC were identified for the study period. Full testing (IHC, *MLH1*-hm or *BRAF* mutation testing and germline sequencing) with conclusive results was obtained in 143 patients. *MLH1*-hm tumors were found in 106 patients (74.1% of the cohort) and a germline MMR mutation was found in 37 patients (25.9% of the cohort). In the other 46 patients with dMMR tumors, further testing was either not feasible or was negative; these patients were excluded from further analysis. Patient characteristics are described in [Table 1](#T1){ref-type="table"}. Forty-eight patients were enrolled on the Columbus LS study (33.6%) and 95 patients (66.4%) were found on routine clinical screening, and there were no statistically significant differences in the patient characteristics in the two patient populations. Of the 106 patients with *MLH1*-hm tumors, 25 patients had confirmed *BRAF* mutation analysis and the remainder had *MLH1* hypermethylation testing. Patients with LS-associated tumors were significantly younger (median 47 vs. 70.5 years at diagnosis, p\<0.0001) and predominantly male (59.5% vs. 42.5% p=0.077) compared to *MLH1*-hm patients. Most patients (72.9% and 71.7% in the LS and *MLH1*-hm groups) were diagnosed at stage II or III, with only 8.2% and 13.2% diagnosed at stage IV in the two groups, respectively. Patients with LS were significantly more often diagnosed with stage III disease compared to patients with *MLH1*-hm tumors (46.0% vs. 26.4%, p=0.022) with a higher likelihood of recurrence (24.3% vs. 11.3%, p=0.040). The division by stage and germline mutation was as follows: For *MLH1* mutations stages I-IV at diagnoses were 0%, 27.3%, 54.5% and 9.1%; for *MSH2* mutations 5.9%, 17.6%, 52.9% and 11.8%; for *MSH6* mutations 40.0%, 60.0%, 0% and 0%; and for *PMS2* mutations 0%, 33.3%, 66.7% and 0%. [Table 1](#T1){ref-type="table"} shows the number of patients with LS and *MLH1*-hm tumors receiving 5-FU based adjuvant chemotherapy in stage II and III disease, respectively. Median duration of follow-up was longer for patients with LS (27.5 months vs. 25.0 months, p=0.032).

Tumor pathology and type of surgery {#S13}
-----------------------------------

[Table 2](#T2){ref-type="table"} describes tumor pathology and type of surgery performed in the two groups. There were no differences in any of the pathology factors between the two groups. Patients with LS had total colectomies performed significantly more often than patients with *MLH1*-hm CRC (27.8% vs. 5.1%, p=0.0047). There were no statistically significant differences in the locations of the tumors with the majority found in the right colon (73.0% and 82.1% in the two groups, p=0.51).

Survival {#S14}
--------

OS and CSS in the two groups are presented in [Figures 1](#F1){ref-type="fig"} and [2](#F2){ref-type="fig"} and [Table 3](#T3){ref-type="table"}. [Supplementary Figures S3--S5](#SD1){ref-type="supplementary-material"} show CSS in the two groups broken down by stage at diagnosis. CSS events were not observed in patients with stage I disease and are not depicted in a figure. [Table 3](#T3){ref-type="table"} presents median survival and hazard ratios for OS and CSS by stage and overall while adjusting for age and stage at diagnosis. The difference in CSS between the two groups was not statistically significant (HR=1.33, p=0.60) after adjusting for the effect of age and stage. Most CSS events occurred in the first 24 months after CRC diagnosis and there was no significant difference between the groups when broken down by stage. OS was significantly longer for patients with LS and remained borderline significant after adjusting for the effect of age and stage (HR=1.96, p=0.095). This was mostly driven by survival difference seen in stage II when broken down by stage (HR=3.97, p=0.079). No difference was seen in OS and CSS when the LS-group was limited to comparing *MLH1* germline mutated patients (n=11) to patients with *MLH1*-hm tumors (n=106) (calculations not shown). Patients with stage II or III cancer who received adjuvant chemotherapy had improved CSS, although not statistically significant (HR=0.48, p=0.25), as compared to those without chemotherapy when including stage and age as covariates. There were better but not significant differences in CSS when comparing the LS-group that received adjuvant chemotherapy to the *MLH1*-hm group receiving adjuvant chemotherapy after adjusting for age and stage (HR:2.72, 95%CI: 0.32, 23.2, p=0.36). There was no significant difference in CSS when comparing patients diagnosed before or after year 2007 (HR: 0.90, p=0.81), and the results of patients with LS vs *MLH1*-hm tumors were similar (HR=1.38, p=0.57 for CSS) after adjusting for time of diagnosis. [Supplementary Table S1](#SD1){ref-type="supplementary-material"} describes the germline mutations in the LS-group.

DISCUSSION {#S15}
==========

In this study, CSS is similar in patients with LS-associated CRC and sporadic *MLH1*-hm CRC. The lack of difference in CSS suggests that the prognosis for CRC is similar in patients with dMMR tumors, whether it is related to germline MMR mutations or sporadic *MLH1* inactivation. OS was longer in patients with LS as shown in [Figure 1](#F1){ref-type="fig"} but after correcting for age and stage at diagnosis the difference was of borderline significance and seems to be driven by patients with stage II disease. Both LS and *MLH1*-hm patients had exceptionally good survival for stage I (5-yr CSS 100%) and stage II (5-yr CSS \>90%) disease; this is better than expected for CRC with proficient mismatch repair activity as has been previously reported.^[@R9]^ Five-year CSS in stage III was 60% in both groups and similar to prognosis in mismatch repair proficient tumors. Benatti et al. looked at the prognostic impact of MSI-high CRC and the efficacy of chemotherapy in a cohort of 1263 CRC patients. In a sub-analysis, patients with germline MMR mutations had better CSS as compared to sporadic MSI-high patients but this impact disappeared in a multivariate analysis where only age and stage at diagnosis predicted CSS.^[@R22]^ Sinicrope et al. looked at germline MMR mutations vs. *MLH1*-hm tumors in a study looking at the benefit of adjuvant 5-fluorouracil (5-FU) chemotherapy. Patients with dMMR tumors suspected to have germline mutations (based on clinical and IHC criteria) had improved survival compared with sporadic dMMR tumors but this association was lost after adjusting for age.^[@R23]^ Although more patients with LS received adjuvant therapy in our study, CSS was not significantly different between the 2 groups according to whether or not they received adjuvant chemotherapy. The interpretation of this analysis is limited due to a small sample size. Not surprisingly, patients with *MLH1*-hm tumors tend to be older at diagnosis and more often female. Methylation and inactivation of genes is believed to be part of normal aging but it is unclear why these tumors occur more frequently in females.

LS-associated tumors were more frequently diagnosed at stage III compared to *MLH1*-hm tumors. This could explain the higher recurrence rates in the LS-associated CRC group. It is possible that higher stage at presentation in younger patients with CRC is related to lack of awareness of this disease in the younger population and lower rates of routine screening colonoscopies. It is possible that some patients with LS were diagnosed before entering this study but many were diagnosed upon their CRC diagnosis and had no knowledge of the germline mutation.

There was no observed difference in pathologic features between the two groups in our study. A study by Hartman et al. analyzed grade, histology and tumor location in sporadic MSI-high tumors vs. LS/probable LS-associated tumors (based on *BRAFV600E* mutation, *MLH1*-hm, cancer history and germline MMR mutations). They found left-sided MSI-high tumors to be more frequently associated with LS. Sporadic MSI-high tumors demonstrated tumor-infiltrating lymphocytes more often (81% vs. 61%) as compared to LS-associated tumors with other pathologic factors being similar.^[@R24]^

In concordance with other studies, very few patients presented with stage IV disease in the two groups. The median OS in stage IV was similar to what would be expected for proficient MMR tumors (23.5 months) in the LS-group but worse in the *MLH1*-hm group (17 months). After adjusting for age there was no significant difference between the two groups (HR 1.96, 95%CI 0.89--4.29). The interpretation of this is limited due to low patient numbers. Venderbosch et al. published survival data on dMMR CRC combining the CAIRO, CAIRO2, COIN and FOCUS clinical trial datasets in patients with stage IV disease. They found that patients with dMMR tumors had worse OS than patients with pMMR tumors (13.6 vs. 16.8 months, HR 1.35 (95% CI 1.13--1.61). The main cause of dMMR in the studies was *MLH1*-hm (30 out of 45 patients) and 73% of them had *BRAF* mutations.^[@R15]^

Our study has some limitations including its retrospective nature and the relatively short median length of follow-up (2 years). Also, the relatively low number of patients gives us limited power to detect small differences in CSS between the two groups, particularly when measuring the effect of adjuvant chemotherapy. However, one of the strengths of our study is the fact that it was limited to patients with either LS or *MLH1*-hm tumors only by definitive molecular diagnosis.

In conclusion, we have shown that there is no statistically significant difference in CSS between LS-associated and *MLH1*-hm CRC in this cohort of patients. The observed difference in median OS became non-significant after correcting for age and stage at diagnosis and is therefore likely confounded by the differences in median age and disease stages between the two groups.

Supplementary Material {#S16}
======================

###### 

Supplemental Figure 1: Cancer-specific survival in stage II in patients with LS-associated CRC and *MLH1*-hm CRC in months.

Supplemental Figure 2: Cancer-specific survival in stage III in patients with LS-associated CRC and *MLH1*-hm CRC in months.

Supplemental Figure 3: Cancer-specific survival in stage IV in patients with LS-associated CRC and *MLH1*-hm CRC in months.
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###### 

Patient characteristics, stage and tumor location

                                   Lynch syndrome (n=37)   *MLH1*-hm (n=106)   p-value
  -------------------------------- ----------------------- ------------------- ------------
  Age (median; Q1,Q3)              47 (35, 58)             70.5 (63,80)        p\< 0.0001
  Sex                                                                          
   Male                            22 (59.5%)              45 (42.5%)          p=0.074
   Female                          15 (40.5%)              61 (57.5%)          
  Race                                                                         
   Caucasian                       33 (89.2%)              88 (89.8%)          p=0.775
   AA                              3 (8.1%)                9 (9.2%)            
   Hispanic                        1 (2.7%)                1 (1.0%)            
  Stage                                                                        
   I                               4 (10.8%)               15 (14.2%)          p=0.022
   II                              10 (27.0%)              48 (45.3%)          
   III                             17 (46.0%)              28 (26.4%)          
   IV                              3 (8.1%)                14 (13.2%)          
   Stage I--III (unknown)          3 (8.1%)                1 (0.9%)            
  Location                                                                     
   Right                           27 (73.0%)              87 (82.9%)          p=0.457
   Left                            7 (18.9%)               11 (10.5%)          
   Rectum                          3 (8.1%)                7 (6.7%)            
  Synchronous                      4 (10.8%)               6 (5.7%)            p=0.459
  Metachronous                     7 (18.9%)               4 (3.8%)            p=0.009
  Received adjuvant chemotherapy                                               
   Stage II                        3 (30%)                 4 (8.3%)            p=0.058
   Stage III                       10 (59%)                11 (39%)            P=0.091
  Recurrence (%)                   9 (24.3%)               12 (11.3%)          p=0.040
  Other cancer diagnosis (%)       13 (34.2%)              27 (25.5%)          p=0.301
  Follow-up time (months)                                                      
  (median; Q1,Q3)                  30.0 (16, 117)          25 (5, 54)          p=0.02
  CEA (n, median; Q1, Q3)          1.2 (0.7, 2.6)          1.9 (1.0, 5.6)      P=0.070

AA = African-American; Q = quartiles; Statistical significance was evaluated by Chi-square for categorical variables and t-test for continuous variables. Significance was set at p\<0.05.

###### 

Tumor characteristics and type of surgery

                         Lynch syndrome (n=37)   *MLH1*-hm (n=106)   p-value
  ---------------------- ----------------------- ------------------- ----------
  Tumor type                                                         
   Adenocarcinoma        27 (77.1%)              78 (74.3%)          
   Mucinous (\>50%)      5 (14.3%)               21 (20.0%)          p=0.473
   Signet ring           3 (8.6%)                3 (2.9%)            
   Medullary             0                       2 (1.9%)            
   Undifferentiated      0                       1 (1.0%)            
  Grade                                                              
   Well                  2 (5.9%)                4 (3.9%)            p=0.641
   Moderately            21 (61.8%)              53 (51.5%)          
   Poorly                11 (32.3%)              45 (43.7%)          
   Undifferentiated      0                       1 (1.0%)            
  Border                                                             
   Infiltrative          22 (91.7%)              66 (89.2%)          
   Pushing               0                       5 (6.7%)            p=0.32
   Focally both          2 (8.3%)                3 (4.1%)            
  Lymph nodes examined                                               
   Mean (SD)             24.8 (16.0)             22.3 (17.5)         p=0.436
  Lymph nodes positive                                               
   Mean (SD)             2.1 (3.7)               1.8 (3.9)           p=0.619
  Size (largest tumor)                                               
   Mean (SD)             5.8 (3.2)               5.9 (2.6)           p=0.922
  Surgery                                                            
   R hemicolectomy       16 (44.4%)              71 (72.5%)          
   L hemicolectomy       6 (16.7%)               11 (11.2%)          p=0.0047
   Subtotal colectomy    2 (5.6%)                8 (8.2%)            
   Total colectomy       10 (27.8%)              5 (5.1%)            
   LAR                   2 (5.5%)                3 (3.0%)            

R = right; L = left; LAR = low anterior resection; SD = standard deviation; Statistical significance was evaluated by Chi-square for categorical variables and t-test for continuous variables. Significance was set at p\<0.05.

###### 

Median overall survival, cancer-specific survival and hazard ratios corrected for age and stage at diagnosis

              Overall survival (mo)   HR (95%CI)   p-value                            Cancer-specific survival (mo)      HR (95%CI)   p-value                                      
  ----------- ----------------------- ------------ ---------------------------------- ---------------------------------- ------------ --------- ---------------------------------- ----------------------------------
  Stage I     NR                      51           [\*](#TFN4){ref-type="table-fn"}   [\*](#TFN4){ref-type="table-fn"}   NR           NR        [\*](#TFN4){ref-type="table-fn"}   [\*](#TFN4){ref-type="table-fn"}
  Stage II    NR                      59           3.97 (0.85--18.5)                  0.079                              NR           NR        1.07 (0.08--13.6)                  0.96
  Stage III   71                      32           1.08 (0.28--4.18)                  0.91                               71           NR        1.11 (0.22--5.64)                  0.90
  Stage IV    23.5                    17           2.07 (0.32--13.5)                  0.45                               23.5         17        2.07 (0.32--13.5)                  0.45
  Overall     NR                      45           1.96 (0.89--4.92)                  0.095                              NR           NR        1.33 (0.46--3.83)                  0.60

HR\>1 signifies that LS has better survival than *MLH1*-hm patients.

Not enough events to calculate.

CI=confidence interval; HR=hazard ratio; Mo=months; NR=not reached.
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